CStone Pharmaceuticals (HKG:2616)

Market Cap	8.16B +161.9%
Revenue (ttm)	221.89M -55.6%
Net Income	-413.21M
EPS	-0.32
Shares Out	1.47B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,554,000
Average Volume	8,695,863
Open	5.43
Previous Close	5.54
Day's Range	5.37 - 5.95
52-Week Range	2.03 - 13.15
Beta	0.52
RSI	58.97
Earnings Date	Mar 26, 2026

About CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 131
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2616

Financial Performance

In 2024, CStone Pharmaceuticals's revenue was 407.21 million, a decrease of -12.21% compared to the previous year's 463.84 million. Losses were -91.21 million, -75.16% less than in 2023.

Financial numbers in CNY